Last reviewed · How we verify
EXG202
At a glance
| Generic name | EXG202 |
|---|---|
| Sponsor | Guangzhou Jiayin Biotech Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD (PHASE1, PHASE2)
- To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXG202 CI brief — competitive landscape report
- EXG202 updates RSS · CI watch RSS
- Guangzhou Jiayin Biotech Ltd portfolio CI